Compare Quest Diagnostics Inc (DGX) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Symbotic Inc — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.06B), while Symbotic Inc trades at $42.65 (market cap $5.62B). The key difference: Quest Diagnostics Inc is far larger — about 4.5× Symbotic Inc's market cap, and Quest Diagnostics Inc pays a 1.52% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Symbotic Inc for 23 Days on average.
| DGX | SYM | |
|---|---|---|
Market Cap | $25.06B | $5.62B |
Volume | 927,361 | 1,339,679 |
Sector | Health | Industrials |
52-Week High | $247.45 | $87.30 |
52-Week Low | $173.49 | $38.22 |
Typical Hold Time | 56 Days | 23 Days |
Enterprise Value | $30.82B | $3.88B |
Dividend Yield | 1.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
SYM trades at $43.31, down 1.9% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth potential with a $22.5 billion backlog but faces profitability challenges with negative net income of -$16.94 million in 2025. Analyst consensus is positive with a $60.33 price target, though recent earnings misses and customer concentration risk remain concerns.
SYM presents a growth opportunity in warehouse automation with significant backlog and expanding market demand, but investors must weigh high valuation multiples against current profitability issues and execution risks. The stock's upside depends on successful margin expansion and diversification beyond its major customer relationship.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
